Pyridazinones and pyrrolones are important building blocks for some important drugs such as the naturally occurring antibacterial pyrrolone, althiomycin; the cardiotonic pyridazinones, pimobendan and levosimendan and the analgesic anti-inflammatory, emorfozan. Therefore, researchers all over the world paid attention to prepare various pyridazinones and pyrroolones derivatives. The variability in the biological response and ease of preparation from the corresponding furanones attracted attention of researchers to explore these two nuclei in the design and synthesis of different analogues. This review article focuses on different biological activities, structure activity relationship and mechanism of action of pyridazinones and pyrrolones derivatives.
Introduction
Pyridazinones and pyrrolones are heterocyclic compounds having many biological activities such as anti-inflammatory [1], analgesic [1], antibacterial [2] and cardiotonic [3] activities. Both pyridazinones and pyrrolones could be synthesized by nucleophilic substitution from the corresponding furanones [1] . Pyridazinones and pyrrolones are fantastic moieties with wide application in clinical use. The most important examples are, Althiomycin 1 which is a naturally occurring alkaloid separated from Streptomyces Althioticus and used as antibiotic through inhibition of protein synthesis [2] . In addition, Pimobendan 2 is a phosphodiesterse III (PDE III) inhibitor and used in management of congestive heart failure [3] . Moreover, Emorfozan 3 was marketed in Japan as an analgesic and antiinflammatory drug [4] . Also, literature reports have also revealed several pyridazinones with vasorelaxant activity such as SK&F-93741 4 a dihydropyridazinone derivative having vasodilator properties [5] . Moreover, levosimendan 5 which is a cyano containing pyridazinone derivative exhibiting cardiotonic activity with dual inotropic and vasodilator activities, so levosimendan used in treatment of congestive heart failure [6] [7] [8] . (Figure1) 
Pyridazinones
Pyridazine is the structural isomer of 1,3-diazine (pyrimidine) and 1,4-diazine (pyrazine). Pyridazine is a planer six membered ring and is considered as a resonance hybrid of two structures 6a and 6b, but the structure 6a is the predominating one [9] .
(Figure 2)
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activities of this moiety such as antihypertensive [16] , platelet aggregation inhibitors [17] , cardiotonic [5] , antimicrobial [18] , analgesic [19] , anti-inflammatory agents. [19] , anticonvulsant [20] , anticancer [21] and (PDE III, V) inhibitors [5, 22] . (Figure  4) 3.1. Anti-inflammatory Activity K. Abouzid et al., [23] synthesized a series of pyridazinones for comparison with diclofenac. Some of the tested compounds revealed more than 50% inhibition of carrageenan-induced rat paw edema at a dose 10 mg/kg. Compounds 8 and 9 showed comparable activity to declofenac after 4hr. The presence of bromine at position 2 in compound 8 or 2,6-dimethylphenyl group in compound 9 increased the anti-inflammatory activity. Meanwhile, A novel 6-aryl-2-(p-sulfamoylphenyl)-4,5-dihydropyridazin-3(2H)-ones was synthesized and tested for their anti-inflammatory activity in carrageenan-induced rat paw edema model by R. Bashir et al., [24] . Compound 10 showed anti-inflammatory activity comparable to that of celecoxib after 5hr. Similarly, K. Abouzid et al ., [25] synthesized a series of compounds containing central bicyclic quinoxaline substituted with a phenyl ring and pyridazinone ring instead of sulfamoylphenyl or sulfonylphenyl group of celcoxib. The phenyl ring was used to fit in to the area occupied by the CF 3 group of celecoxib. Bicyclic quinoxaline nucleus attached to pyridazinone and phenyl substituents in compounds 11 and 12 produced potent anti-inflammatory activity especially chloro analogue 12. Moreover, K. Abouzid et al., [26] introduced a series of aryl ethenyl and aryl ethyl pyridazinone derivatives. The results indicated that synthesized compounds exhibited good anti-inflammatory activity with safe gastrointestinal profile and compound 13 in which ethyl linker between the dihydropyridazinone ring and the aryl moiety more potent than derivatives with ethyenyl linker. D.S. Dogruer et al., [27] synthesized a series of 4,6-diphenyl-3(2H)-pyridazinones substituted at two position of pyridazinone with 4-arylpiperazin-1-yl-carbonylalkyl moieties. All synthesized compounds were tested for their anti-inflammtory activity using carrageenaninduced rat paw edema at a dose 10 mg/kg and compound 14 showed significant anti-infalammatory activity. Moreover, a novel series of 4-phenyl and 4-4-(2-chlorophenyl)-6-(5-chloro-2-oxo-3H-benzoxazol-7-yl)-3(2H)-pyridazinones were synthesized and tested for anti-infalammatory activity using rat paw edema method and in vitro screening assay against cyclooxygenases COX-1 and COX-2. Compounds 15 and 16 showed a comparable activity to indomethacin with inhibition% of 49.7, 53.6 and 56.8, respectively, which support the results of COX inhibitory activity screening, B. Okcelik et al., [28] . Also, Z. Ozdemir et al., [29] reported the synthesis of novel series of 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(substitutedbenzal)hydrazine derivatives and evaluated their antiinflammatory activity using carrageenan-induced rat paw edema method. Compounds 17 and 18 gave inhibition % (35.0 and 36.0%), respectively comparable to that of indomethacin (39.4%). Sahin et al., [30] synthesized a series of 6-substituted-3(2H)-pyridazinone-2-ylacetate and tested for their antiinflammatory activity using carrageenan-induced rat paw edema method. Compound 19 exhibited the highest inhibition (41.6%) comparable to indomethacin (43.1%). Additionally, it did not show gastric lesion in treated rats. M.M. Saeed et al., [31] synthesized a series of pyridazine and pyridazinone derivatives, the target compounds were tested for their anti-inflammatory and ulcerogenic properties using indomethacin as standard drug. Compounds 20 and 21 showed anti-inflammatory activity of (42.6 % and 31%), respectively, which are more comparable to indomethacin (40.3%). Moreover, both compounds exhibited a safe gastric profile and selective COX-2 inhibition in the MTT assay. C Barberot et al., [32] synthesized a series of pyridazinones and tested as anti-inflammatory agents through reduction of IL-8 level and compound 22 was the most active compound. (Figure 5) 3.2. Analgesic activity M. Asif et al., [33] synthesized a series of 6-phenyl-4-substituted benzylidine tetrahydropyridazin-3(2H)-one derivatives and evaluated their analgesic activity against aspirin [16] synthesized a group of 1,2,4-triazol-3-yl-4,5-dihydropyridazin-3(2H)-one derivatives. Results indicated that compounds with structural features of the general formula 32 showed the maximum antihypertensive activity. Indeed, M. Imran et al., [37] synthesized four pyridazinone derivatives and molecular docking studies of these compounds was carried out on human angiotensin converting enzyme (ACE). Compound 33 exhibited the highest scores in docking study and so tested for ACE inhibitory activity using Dojindo ACE Kit-WST test kit and revealed promising activity (IC 50 = 5.78 µg/mL) compared to that of lisinopril (IC 50 = 0.85 µg/mL). From this research study, authors concluded that incorporation of amino and carboxylic acid groups into the structure of pyridazinone derivatives can enhance the ACE inhibitory activity of this class of compounds. Moreover, R. Mishra et al., [38] introduced a series of 4,5-dihydro-1H-(1,2,4-triazol-3-yl)-4,5-dihydropyridazin-3(2H)-one derivatives and evaluated their antihypertensive activity using Tail Cuff method. This study revealed that compounds 34 and 35 reduced the mean arterial blood pressure (MABP) by (41.84 and 40.98%), respectively in comparable results to the standard drugs propranolol and hydralazine (41.40 and 41.76%), respectively. Vikas Jakhmola et al., [39] 3.4. Vasorelaxant activity K. Abouzid et al., [40] synthesized three series of pyridazinones to identify potential vasodilatory cardiotonic lead compounds. Compounds, 38 and 39 showed higher fit scores to the developed pharmacophore. The vasorelaxant activity was tested using isolated main pulmonary artery of the rabbit using Milrinone as a reference drug. R. Bansal et al., [41] synthesized Abdelbaset et al.
a series of dihydropyridazin-3(2H)-ones and evaluated as vasodilators using rat thoracic aortic rings. Compound 40 revealed vasorelaxation activity higher than that of hydralazine and equal to SK&F-93741 (IC 50 = 0.199, 0.316 and 0.199), respectively. SAR study of these compounds revealed that substitution of pyridazinone ring with phenyl moiety in position two or sex cancelled the vasorelaxant activity. (Figure 8) 
Platelet aggregation inhibitory activity
T. Costas et al., [42] synthesized new 2,6-disubstituted pyridazinone derivatives and tested their antiplatelet effect. Compound 41 showed a comparable antiplatelet activity to aspirin. Also, A series of 6-(4-(substituted-amino)phenyl)-4,5-dihydro-3(2H)-pyridazinones was synthesized by S. Thota et al., [17] . All the tested compounds exhibited significant platelet aggregation inhibitory activity. Compounds 42 and 43 were found to be more potent than aspirin. Moreover, E. Sotelo et al., [43] synthesized a series of 6-phenyl-3(2H)-pyridazinones with potential antiplatelet effect. Compound 44 showed the highest platelet aggregation inhibition with IC 50 value of (15 µM). Additionally, R. Laguna et al., [44] synthesized a series of 6-aryl-5-oxygenated substituted pyridazinones and evaluated as platelet aggregation inhibitors in a dose-dependent manner. Compounds 45 and 46 revealed higher potency than standard drug sulfinpyrazone (IC 50 = 60 and 70 µM, respectively). Moreover, measurement of intracellular cAMP level indicated that activity is independent on cAMP PDEIII level in intact cells. Hence, authors suggested that the target pyridazinones may be acting by another mechanism. From the results, it is obvious that oxidation of alcoholic group into aldehydic group and further into carboxylic acid group diminishes the platelet aggregation inhibitory activity of these compounds. (Figure 9) 3.6. Phosphodiesterases inhibitory activity D. Kumar et al., [5] synthesized a group of 2-substituted-6-(4-acylaminophenyl)-4,5-dihydropyridazin-3 (2H)-ones as potent inotropic and vasorelaxant agents through inhibition of PDE III.
The synthesized compounds was evaluated for cardiotonic activity using isolated rat atria and for vasorelaxant activity using descending thoracic aortic rings of Wistar rats precontracted with phenylephrine (10 -6 mol/L). [47] synthesized a series of pyridopyridazin-3(2H)-one derivatives and evaluated their anticancer activity against MCF-7 breast cancer. Compound 54 exhibited significant activities with IC 50 of 61.3 µM. SAR results indicated that amidic group in the structure of pyridopyridazin-3(2H)-one is essential for anticancer activity. A novel pyridazinone derivatives carrying benzenesulfonamide moiety were prepared by I. Rathish et al., [48] Compound 55 exhibited remarkable activity against leukemia cancer cell line SR and non-small cell lung cancer cell line NCI-H522 with GI 50 less than 0.1 µM. Also, it showed significant activity against different cancer cell lines with GI 50 less than 1.0 µM. Y. Liu et al., [49] [63] synthesized a series of 4-(benzylidene or substituted benzylidene)-6-(3-nitrophenyl)-4,5-dihydropyridazin-3(2H)-ones 73a-c. The anticonvulsant activity of these compounds was evaluated using maximal electroshock (MES) induced seizure method. The synthesized compounds exhibited significant anticonvulsant activity against MES induced seizure in albino mice after administration of 50 mg/Kg. Additionally, P.S. Banerjee et al., [64] synthesized a series of substituted 6-aryl-2,3,4,5-tetrahydro-3-pyridazinones and 6-aryl-2,3,4,5-tetrahydro-3-thiopyridazinones and evaluated as anticonvulsant agents using MES-induced seizure test. Compound 74 showed significant anticonvulsant activity. Similarly, K.C. Samanta et al., [20] synthesized some pyridazinone derivatives and evaluated their anticonvulsant activity by MES method. Compound 75 revealed the highest activity with 100% recovery as phenytoin. S. Partap et al., [65] synthesized a series of new hybrid benzimidazole containing pyridazinones derivatives that was evaluated as anticonvulsant using MES method and (scPTZ)-induced seizure. Compound 76 showed a significant anticonvulsant activity in both models with ED 50 of 25.10 and 85.33 mg/kg in the MES and scPTZ methods, respectively which is compared to phenytoin with ED 50 of 9.5 and >300 mg/kg, receptively in both models. Moreover, A. Husain et al., [66] synthesized a series of pyridazinones and studied their effect as anticonvulsant agents through molecular docking. Compound 77 revealed the highest docking scores and concluded this compound may potentiate GABA mediated chlorine channel opening. M. Asif et al., [67] introduced methylindole derivative of some 6-aryl-4,5-dihydropyridazin-3(2H)-ones. Compounds 78-80 gave the highest protection against MES, INH and scPTZ-induced convulsion models. (Figure 16) 
Pyrrolones

(pyrrolin-2-ones) are the five-membered heterocyclic ring can be synthesized by different methods which based on heterocyclization of various Schiff bases with maleic anhydride [68, 69] and reaction of furanone derivatives with amines [70, 71] .
Biological activity of pyrrolones
Pyrrolone considered as an important nucleus with variable biological activities including antibacterial [72] , antiinflamatory [72] , analgesic, antimycobacterial [73] , antidepressant [74] , antiviral [75] and antitumor activities [76] . (Figure 17) 
Anti-inflammatory activity
A series of pyrrol-2-one was prepared by A. Husain et al., [72] , the anti-inflammatory activity results showed that compound 81 has comparable activity to declofenac. S. Khokra et al., [77] synthesized a series of quinolinylpyrrolone derivatives and tested as anti-inflammatory agents using carrageenan induced paw edema. Compounds 82 and 83 gave 53% and 63% inhibition, respectively. These results indicate that conversion of secondary -NH-group into tertiary moiety by benzyl amine increased the anti-inflammatory activity. Y. Ali et al., [78] [80] synthesized a series of pyrrolone derivatives, compounds 88 and 89 exhibited significant activity comparable to declofenac. Also, the two compounds revealed a higher safety profile twice than declofenac (1.3, 1.3 and 2.6), respectively. (Figure 18) 
Antimicrobial activity
A. Husain et al., [72] introduced a series of pyrrole-2-one derivatives, the pyrrole-2-one 90 showed significant activity against S. aureus with MIC (6.5 µg/mL) and good activity against E.coli with MIC (15 µg/mL. A novel 2(3H) pyrrolone derivatives were synthesized by A. Ahmad et al., [81] and evaluated as antibacterial agents. Compound 91 gave the strongest antibacterial activity against S. aureus, E. coli and P. aeruginosa which was equipotent to ciprofloxacin (MIC = 6.25µg/ML). Moreover, N.G. Kandile et al., [82] synthesized a series of indolyl-pyrrolones and tested their antibacterial activity. Compound 92 exhibited equipotent activity to chloramphenicol against E. coli with MIC of 2.5 µg/ML. (Figure 19 ) A. Husain et al., [83] synthesized a series of pyrrolone and Nbenzyl pyrrolone derivatives. The antibacterial evaluation exhibited that compound 93 was the strongest antibacterial with MIC of 6.25 µg/mL against E.coli and P. aeruginosa and 12.5 µg/mL against S. aureus comparable to ciprofloxacin (MIC = 6.5 µg/ML). Also, S. Khokra et al., [77] synthesized a series of quinolinyl-pyrrolone derivatives. Secreening results revealed that compound 94 has the highest antibacterial activity with MIC of 12.5 µg/mL against E.coli and P. aeruginosa and 6.25 µg/mL against S. aureus compared to ciprofloxacin (MIC = 6.5 µg/Ml). M.F. El-Shehry et al., [71] synthesized a series of pyrrolone derivatives and compound 95 exhibited remarkable antibacterial activity with inhibition zone diameter 5 and 7 mm against S. aureus and E.coli, respectively which more potent than Penicillin (32 and 15mm), respectively. In addition, A. Husain et al., [84] synthesized a series of pyrrolone derivatives and tested as antimicrobial agents against S. aureus and E. coli and C. albicans. Compounds 96 and 97 revealed the strongest activity against S. aureus (MIC = 20 and 15 µg/mL), respectively and against C. albicans (MIC = 10 µg/mL). (Figure 19) 
Anti-mycobacterial activity
A. Husain et al., [85] synthesized a series of pyrrole-2-ones. Among these compounds, compound 98 showed the most promising antimycobacterial activity with IC 50 of (11.34 µg/mL). [87] synthesized 3-hydroxy-5-nitrophenyl-4-pivaloyl-2,5-dihydro-2-pyrrolone 102. The results indicated that compound 102 exhibited antitumor activity against lung cancer with growth inhibition of 55% and CNS cancer with growth inhibition of 67%. Additionally, E. Lattmann et al., [88] synthesized a series of 5-hydroxy-5-aryl-pyrrol-2-ones, compound 103 stopped growth of colon and pancreatic cancer models and act as Cholecystokinin-1 receptor antagonist with IC 50 of 0.008 and 0.4 µM against CCK-A and CCK-B, respectively which are more potent than standard lorglumide (IC 50 of 0.17 and >10 µM), respectively. Moreover, W.S. Abou-Elmagd et al., [89] [90] synthesized a series of indolylpyrrolone derivatives to evaluate them as pim1 kinase inhibitors and compound 107 gave the highest activity with ID 50 of 4.5 µM. (Figure 23 ).
Conclusion
The importance of pyridazinone and pyrrolone derivatives arises from their variable biological activities such as antiinflammatory, antibacterial, cardiotonic, antimycobacterial, anticoagulant, antihypertensive, anti-mycobacterial, and most importantly their anticancer activities. It is obvious that medicinal chemists from research groups all over the world has synthesized different substituted pyridazinones and pyrrolones to explore their biological activity and sometimes their drug target. From this review article, an important conclusion could be identified; In spite of the known old anti-inflammatory activity of these scaffolds, there is a direction in the future towards utilization of these two nuclei in the design of anticancer molecules as tubulin polymerase or kinase inhibitors.
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